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vidence-based medicine has been promoted as 
an ideal in medical practice.1,2 Clinicians are en-
couraged to search the literature, to retrieve and 
critique articles, and ultimately to apply their conclu-
sions to bedside decisions.3 However, given the tremen-
dous volume of medical literature, this is no easy task.
Here, we highlight 5 notable articles for general in-
ternal medicine published in 2008 and 2009, with sum-
maries of their key findings and focused discussion of 
salient points. For each article, a clinical vignette is used 
to illustrate how physicians might apply the findings of 
the study to their own practices. We then describe the 
strategy we used to select the studies, along with a gen-
eral approach to surveying the vast and growing medical 
literature for “important” papers, recognizing that the 
judgment of importance is both personal and subjective. 
Use of beta-blockers during noncardiac surgery
Clinical  vignette.  A  54-year-old  man  is  seen  for  pre-
operative medical assessment before elective total arth-
roplasty of the left knee. He has type 2 diabetes mellitus, 
which is managed with insulin therapy. He is not taking 
any other medications and, notably, is naive for beta-
blockers. He has no known history of coronary artery 
disease or renal insufficiency, and his functional cap-
acity is normal. He inquires about strategies to lower his 
perioperative cardiovascular risk.
Summary of findings. The balance between the bene-
fits and harms of using beta-blockers before noncardiac 
surgery has long been a topic of interest for internists in-
volved in preoperative risk assessment. To address this 
topic, Bangalore and colleagues performed a systematic 
review and meta-analysis of 33 randomized controlled 
trials that evaluated a total of 12 306 patients and found 
that beta-blockers (either given to beta-blocker-naive pa-
tients, or continued versus discontinued in trials that in-
cluded patients with pre-existing beta-blocker therapy) 
were not associated with any significant reduction in the 
risk of all-cause mortality, cardiovascular mortality or 
heart failure. However, they were associated with a 35% 
reduction (odds ratio [OR] 0.65) of nonfatal myocardial 
infarction at the expense of a 101% increase (OR 2.16) 
in nonfatal stroke.4 In a comparison of patients treated 
with beta-blockers and controls, there was an absolute 
reduction in the risk of nonfatal myocardial infarction 
of 1.7% (number needed to treat [NNT] 63) but an abso-
lute increase in the risk of nonfatal stroke of 0.4% (num-
ber needed to harm [NNH] 275). Relative to controls, 
beta-blockers were also associated with a greater risk of 
perioperative bradycardia (NNH 22) and perioperative 
hypotension requiring treatment (NNH 17). Among the 
trials included in the analysis, the Perioperative Ischemic 
Evaluation  Study  (POISE)  trial5  carried  the  greatest 
weight. There were no sponsors for this meta-analysis.
Implication  and  perspectives.  This  study  confirmed 
what some already suspected on the basis of the POISE 
trial:5 that perioperative beta-blockade is associated with 
a reduced risk of myocardial infarction at the cost of an 
increased risk of stroke. More importantly, this study 
Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli 
FH. Perioperative ß blockers in patients having non-cardiac sur-
gery: a meta-analysis. Lancet 2008;372(9654):1962–1976. Available 
from: http://www.thelancet.com/journals/lancet/article/PIIS0140-
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quantified the treatment effects in absolute terms. At the 
population level, for every stroke incurred, more than 4 
myocardial infarction events may be averted with beta-
blocker  therapy.  The  American  College  of  Cardiology 
Foundation and the American Heart Association have 
now updated their guidelines for perioperative cardio-
vascular  evaluation  for  noncardiac  surgery6  to  reflect 
the newer data presented in this study. Absolute risk 
reductions (and NNTs) are, however, linked to baseline 
risks for specific types of events. As a result, there may 
not be a single overriding treatment recommendation 
that applies to all patients. The findings of this study 
may allow clinicians to more meaningfully discuss the 
benefits and risks of beta-blocker therapy with patients 
while negotiating a mutually agreeable treatment plan. 
There are specific patient profiles (e.g., documented cor-
onary artery disease with a high risk of ischemic cardiac 
events) for which the potential benefits of beta-blockers 
may nonetheless be justified, even in light of this newly 
recognized risk of stroke.
Resolution of the clinical vignette. For most patients 
undergoing noncardiac surgery, current evidence does 
not support starting beta-blocker therapy as a strategy 
to lower perioperative cardiovascular risk. However, in 
individuals at high risk for ischemic heart disease, the 
benefit of beta-blockers may outweigh the risk of stroke 
and possible death. The patient in this vignette is esti-
mated to have only an intermediate risk of perioperative 
myocardial  infarction,  given  the  planned  orthopedic 
surgery and his history of diabetes mellitus.6 In this con-
text, the anticipated benefit compared to risk is probably 
not high enough to warrant beta-blocker therapy. How-
ever, beta-blocker therapy might be appropriate for a pa-
tient with higher risk of ischemic cardiac events. 
Revascularization for renal artery stenosis
Clinical vignette. A 62-year-old woman is referred for 
evaluation of severe hypertension. There is ultrasono-
graphic evidence of a small and atrophic right kidney. 
Her  family  physician  suspects  unilateral  renal  artery 
stenosis.
Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, et al. Revasculariza-
tion versus medical therapy for renal-artery stenosis. N Engl J Med 
2009;361(20):1953–1962. Available from: http://content.nejm.org/
cgi/content/full/361/20/1953.
Summary of findings. Atherosclerotic renovascular dis-
ease is a common condition associated with substantial 
risk  of  cardiovascular  death.7  Although  treatment  has 
traditionally centred on revascularization, this practice 
has been questioned.8 The Angioplasty and Stenting for 
Renal Artery Lesions (ASTRAL) trial was designed to 
compare the combination of revascularization and med-
ical therapy with medical therapy alone for the treat-
ment  of  this  condition.7  This  study  was  supported  by 
research grants from the Medical Research Council UK, 
Kidney Research UK and Medtronic. In this multicentre, 
randomized, nonblinded clinical trial, 806 patients were 
followed  over  5  years.  The  investigators  found  simi-
lar rates of renal deterioration, renal events (i.e., acute 
kidney injury, initiation of dialysis, renal transplanta-
tion, nephrectomy or death from renal failure), major 
cardiovascular  death  and  all-cause  mortality.  Early 
periprocedural complications (i.e., occurring within 24 
hours) were reported for 31 (9%) of the 359 patients who 
underwent revascularization; these included 19 serious 
complications (e.g., myocardial infarction, renal embol-
ization, occlusion or perforation of the renal artery, or 
digital or limb amputation). Late adverse events associ-
ated with revascularization (i.e., after 24 hours but with-
in 1 month) were reported in 55 patients (20%), and these 
included 12 serious complications (including 2 deaths). 
 
Implication  and  perspectives.  The  authors  of  this 
study found no significant benefit of attempted revas-
cularization in patients with atherosclerotic renovascu-
lar disease; rather, they reported substantial risks. The 
findings of the ASTRAL trial add to the evidence against 
combining  revascularization  therapy9  with  medical 
management for renal artery stenosis (i.e., statins, anti-
platelet agents and optimal control of blood pressure). 
These  findings  indicate  that  the  potentially  harmful 
and costly investigations used to diagnose renal artery 
stenosis  (e.g.,  computed  tomography  with  intravenous 
administration of contrast agent, catheter angiography, 
and magnetic resonance imaging with administration of 
gadolinium) will not lead to an advisable treatment strat-
egy. As such, internists should consider avoiding such in-
vestigations entirely. 
 
Resolution of clinical vignette. This patient likely has 
atherosclerotic stenosis of the renal artery, complicated 
by hypertension. In contrast to the traditional practice 
of revascularization, the focus of this patient’s manage-
ment should be to treat modifiable cardiovascular risk 
factors and to optimize blood-pressure control. On the 
basis of this new evidence, further investigation for renal 
artery stenosis is discouraged.
Open Medicine 2010;4(4):e182Dabigatran for atrial fibrillation
Clinical  vignette.  An 80-year-old woman is receiving 
warfarin for atrial fibrillation. However, she struggles to 
maintain the international normalized ratio (INR) with-
in the therapeutic range (between 2.0 to 3.0). She finds 
routine monitoring cumbersome and difficult.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, 
et al. Dabigatran versus warfarin in patients with atrial fibrillation.  
N Engl J Med 2009;361(12):1139–1151. Available from: http://content.
nejm.org/cgi/content/full/361/12/1139. 
Summary  of  findings.  Dabigatran  is  a  new  oral  dir-
ect  thrombin  inhibitor.  The  Randomized  Evaluation 
of  Long-Term  Anticoagulation  Therapy  (RE-LY)  study 
group  designed  and  performed  a  randomized  clinical 
trial comparing warfarin with dabigatran (110 mg or 150 
mg twice daily) for the prevention of cardioembolism in 
atrial fibrillation.10 This study was supported by a grant 
from Boehringer Ingelheim and was coordinated by the 
Population Health Research Institute (Hamilton, Ont., 
Canada), which “independently managed the database 
and performed the primary data analyses.”10 Warfarin 
was adjusted locally to an INR of 2.0 to 3.0, and the INR 
was measured at least monthly. Outcomes analyzed for 
18 113 participants from 44 countries demonstrated that 
dabigatran 110 mg twice daily was associated with rates 
of stroke and systemic embolism similar to those ob-
tained with warfarin (relative risk [RR] 0.91, p < 0.001 
for noninferiority) and lower rates of major bleeding (RR 
0.80, p = 0.003). Dabigatran at a dose of 150 mg twice 
daily was associated with lower rates of stroke and sys-
temic embolism than warfarin (absolute risk reduction 
[ARR] 0.58% per year, RR 0.66, p < 0.001 for superior-
ity), with similar rates of major bleeding (RR 0.93, p = 
0.31). However, the risk of hemorrhagic stroke was sig-
nificantly greater among patients treated with warfarin 
(annual rate 0.38%) than among those treated with dabi-
gatran at either dose (0.12% per year, RR 0.31, p < 0.001 
with 110-mg dose, 0.10% per year, RR 0.26, p < 0.001 
with 150-mg dose). 
Implication  and  perspectives. Warfarin, a vitamin K 
antagonist, has been the cornerstone of antithrombotic 
therapy for patients at high risk of cardioembolism in the 
setting of atrial fibrillation. However, warfarin therapy is 
cumbersome because of its narrow therapeutic window 
and the associated hemorrhagic risk. As a result, fre-
quent laboratory monitoring is required, and the patient 
must be cautious about potential interactions with other 
drugs and food. This study introduces a new treatment 
paradigm, with dabigatran as an alternative to warfarin 
for anticoagulation, and presents impressive efficacy and 
safety evidence favouring the new drug. The use of this 
oral direct thrombin inhibitor may simplify previously 
complex dosing regimens, and it may mitigate the need 
for routine monitoring. However, several issues need to 
be resolved before this drug can be adopted into wide-
spread  clinical  practice:  the  balance  between  relative 
benefits and harms of the 2 doses must be determined; 
provincial  and  national  approvals  must  be  obtained; 
pricing must be determined to ensure affordability for 
the patient; and cost-effectiveness must be assessed (i.e., 
net costs to the system).
Resolution of clinical vignette. The physician discusses 
with the patient the possibility of using dabigatran, rather 
than  warfarin,  for  systemic  anticoagulation.  However, 
given the uncertainty about the issues described above, this 
patient decides to continue her warfarin therapy for now.
Duration of anticoagulation for deep venous 
thrombosis
Clinical  vignette.  A  22-year-old  female  college  student 
presents to the anticoagulation clinic for follow-up recom-
mendations after completing 6 months of therapeutic anti-
coagulation for idiopathic deep venous thrombosis (DVT).
Prandoni P, Prins MH, Lensing AWA, Ghirarduzzi A, Ageno W, Imberti 
D, et al. Residual thrombosis on ultrasonography to guide the dura-
tion of anticoagulation in patients with deep venous thrombosis: 
a randomized trial. Ann Intern Med 2009;150(9):577–585. Available 
from: http://www.annals.org/content/150/9/577.full.
Summary  of  findings.  The  optimal  duration  of  anti-
coagulation after initial DVT remains unclear, and it is 
uncertain which patients would benefit from prolonged 
therapy to reduce the risk of recurrence. This Italian trial 
enrolled 538 consecutive outpatients with a first episode 
of  acute  proximal  DVT.11  The  study  had  no  external 
sources of funding. Patients initially received anticoagu-
lation for 3 months (if they had secondary DVT) or 6 
months (for unprovoked DVT). Patients were then ran-
domly assigned to fixed-duration anticoagulation (i.e., no 
further  treatment)  or  flexible-duration  anticoagulation 
guided by ultrasonographic evidence of residual thrombi 
(i.e., up to 9 months for secondary DVT or 21 months for 
unprovoked DVT). Anticoagulation was discontinued if 
the veins were recanalized, as indicated by ultrasonog-
raphy at 3, 9, 15 and 21 months. Outcome assessment for 
recurrent  venothromboembolism  revealed  a  decreased 
risk (adjusted hazard ratio [HR] 0.64) associated with 
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Open Medicine 2010;4(4):e183ultrasound-guided  anticoagulation  (11.9%)  relative  to 
fixed-duration anticoagulation (17.2%). Among patients 
with  unprovoked  DVT,  pulmonary  embolism  (PE)  oc-
curred in 8 patients (5%) treated with flexible-duration 
anticoagulation and in 7 patients (5%) treated with fixed-
duration anticoagulation. Among patients with second-
ary  DVT,  PE  occurred  in  1  patient  (1%)  treated  with 
flexible-duration  anticoagulation  and  3  patients  (3%) 
with fixed-duration anticoagulation. The occurrence of 
incident pulmonary embolism appeared to be similar be-
tween the groups. There were no significant differences 
between the groups in bleeding complications or death.
Implication and perspectives. Patients with DVT asso-
ciated with transient, reversible risk factors commonly 
receive anticoagulation for a minimum of 3 months, and 
those with unprovoked DVT generally receive at least 6 
months of therapy.12 The evidence from this study sug-
gests  that  ultrasonography  to  detect  residual  venous 
thrombosis  is  a  powerful  and  promising  tool  to  help 
identify  which  patients  would  benefit  most  from  pro-
longed anticoagulation.11 Future areas of research would 
be reconciliation of ultrasound-guided anticoagulation 
with increased D-dimer levels (another predictor of re-
current DVT)13 in an evidence-based treatment strategy, 
assessment of the cost-effectiveness of serial ultrasonog-
raphy, and determination of the optimal duration of anti-
coagulation therapy if recanalization is never achieved. 
Clearly, for clinicians adopting an ultrasound-guided ap-
proach to treatment, measures should be implemented 
to ensure that patients are not lost to follow-up.
Resolution of clinical vignette. For this patient, follow-
up ultrasonography is ordered after 6 months of thera-
peutic anticoagulation to determine if there is evidence 
of a residual thrombus with or without recanalization. 
In the absence of recanalization, anticoagulation therapy 
should be extended, with repeat ultrasonography sched-
uled  in  another  3  months  to  reassess  for  recanaliza-
tion and to determine whether anticoagulation therapy 
should be continued any longer. 
Acetylsalicylic acid for prevention of vascular 
disease
Clinical  vignette.  A  healthy  48-year-old  woman 
has  been  taking  low-dose,  over-the-counter  acetyl-
salicylic  acid  (ASA)  because  she  read  an  article   
in  a  popular  magazine  recommending  low-dose  ASA 
toprotect against strokes and heart attacks. She asks her 
physician for advice.
Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et 
al. Aspirin in the primary and secondary prevention of vascular 
disease: collaborative meta-analysis of individual participant data 
from randomised trials. Lancet 2009;373(9678):1849–1860. Available 
from: http://www.thelancet.com/journals/lancet/article/PIIS0140-
6736%2809%2960503-1/fulltext. 
Summary of findings. This systematic review and meta-
analysis by the Antithrombotic Trialists’ Collaboration 
aimed to determine the benefits and risks of ASA ther-
apy.14 Individual-level data from 6 primary prevention 
trials (assessing ASA doses ranging from 100 mg to 500 
mg in 95 456 patients) and 16 secondary prevention trials 
(17 029  patients)  were  analyzed  to  compare  outcomes 
for  ASA  therapy  and  no  ASA.  The  primary  outcomes 
of interest were serious vascular events (a composite of 
myocardial infarction, stroke and cardiovascular death), 
major coronary events, stroke, all-cause mortality and 
major  extracranial  bleeding.  Meta-analysis  of  the  pri-
mary prevention trials revealed that ASA was associated 
with a lower rate of serious vascular events than no ASA 
(absolute event rate 0.51% v. 0.57% per year; NNT 1667). 
The rate of major bleeding was greater with ASA (ab-
solute event rate 0.10% v. 0.07% per year; NNH 3333). 
ASA was associated with fewer serious vascular events 
when used for secondary prevention (absolute event rate 
6.7% v. 8.2% per year; NNT 67) but also resulted in more 
bleeding (0.25% v. 0.06% absolute event rate per year; 
NNH 526). The sponsors of the study had no role in study 
design, data collection, data analysis, data interpretation 
or writing of the paper. The sources of funding for each 
individual trial were described in the original publica-
tions. This meta-analysis was not funded.
Implication and perspectives. Although it is well es-
tablished that ASA reduces the risk of thrombosis at the 
expense of increasing the risk of bleeding, the balance 
between  benefit  and  risk  was  less  certain  before  this 
study.15 Here, the Antithrombotic Trialists’ Collaboration 
provides evidence for substantial net benefit of ASA in 
secondary prevention, but the magnitude of benefit was 
less impressive for primary prevention. The balance of 
risks and benefits can be represented by the “likelihood 
of being helped versus harmed” metric (LHH, a ratio of 
NNH divided by NNT):16,17 in this study, the LHH was 
8 for secondary prevention and 2 for primary preven-
tion. For every 10 000 patients treated with ASA for sec-
ondary prevention, 149 serious vascular events may be 
prevented at the expense of 19 major bleeding events. 
Conversely, among 10000 people who take ASA for pri-
mary prevention, 6 serious vascular events may be avert-
ed, but 3 major bleeding events may occur. This study 
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Open Medicine 2010;4(4):e184refines the estimates of treatment effects and clarifies 
the  risk–benefit  ratio  for  specific  patient  populations. 
The findings validate that the benefits of ASA for sec-
ondary prevention of cardiovascular events exceed the 
bleeding hazards, irrespective of age or sex. However, 
this article raises questions about the value of ASA in 
primary prevention.
Resolution of clinical vignette. The physician advises 
the patient that, given her current risk, the expected ab-
solute benefit of ASA therapy for primary prevention is 
small and must be weighed against the increased risk of 
major bleeding. The physician concludes that, at present, 
there is no compelling reason that this patient should 
continue low-dose ASA therapy. 
Surveillance for important studies
Judging importance is an invaluable skill. Various rat-
ing scales have been proposed as tools to assess the im-
portance of published articles. For example, Lawrence 
and colleagues18 proposed 6 dimensions relevant to rat-
ing the importance of articles: importance to one’s own 
clinical practice (i.e., relevance); importance to clinical 
practice in general; importance from a local, national 
or international public health perspective; importance 
to  the  general  advancement  of  our  collective  medical 
knowledge;  ease  with  which  the  new  information  can 
be applied to current practice; and impact that the new 
information is likely to have on the health outcomes of 
those affected by, or at risk of, the disease or condition 
addressed by the study. 
Although  the  concept  of  training  clinicians  to  be 
“evidence-based  practitioners”  (i.e.,  to  independently 
retrieve, appraise and apply best evidence) is appealing, 
physicians unfortunately face many recognized barriers 
to this approach.19 Most notably, time constraints limit 
their opportunities to search and review, in real time, 
new information that is likely to affect decisions in clin-
ical practice.20–22  Moreover, many physicians admit that 
they lack the skills required to use literature databases 
and  to  properly  appraise  studies.21–25  Guyatt  and  col-
leagues,19 leading enthusiasts of evidence-based medi-
cine, have acknowledged that it is unrealistic to expect 
all care providers to be “evidence-based practitioners” 
who are able to appraise raw evidence from scratch. It is, 
however, crucial for all providers, as “evidence users,” to 
gain some fundamental skills in flagging important evi-
dence and incorporating it into practice.19 
It is estimated that most internists spend 4 to 5 hours 
per week reading medical articles, and that they read 
only the abstracts for about two-thirds of the articles 
they encounter.26 It also appears that the typical intern-
ist relies on journal editors to provide rigorous and use-
ful information.26 As such, given internists’ limited time 
for critical reading, there is a pattern of heavy reliance 
on  summaries  and  prescreened  articles,  as  provided 
by others, to survey the literature for relevant informa-
tion.19,26,27  Reassuringly,  “evidence  users”  who  refer  to 
secondary sources for pre-appraised evidence can still 
become highly competent, up-to-date practitioners who 
are able to deliver evidence-based care.19 
We  recommend  the  use  of  evidence-based,  filtered 
summaries of articles from selected journals (e.g., ACP 
Journal Club and ACP Journal Club PLUS [www.acpjc.
org], Evidence-Based Medicine for Primary Care and 
Internal  Medicine  [ebm.bmj.com]  and  The  Cochrane 
Library  [http://www.thecochranelibrary.com/view/0/
index.html]) for surveillance of the literature.20,28 These 
secondary sources have been developed to identify stud-
ies that meet predefined criteria of importance,18 which 
are then critically appraised by clinical experts. Qualify-
ing studies are screened for relevance to a broad range 
of medical practices, both for generalists and special-
ists. These resources appear to be useful in facilitating 
continuing medical education and focus on identifying 
the  most  sound,  most  relevant  and  “highest-impact” 
studies.28  To  paraphrase  Ockham’s  razor  (“Lex  parsi-
moniae”), just keep it simple. 
We used these information services and considered the 
rating scale of Lawrence and colleagues18 to identify the 5 
notable articles published in 2008 and 2009 in the disci-
pline of general internal medicine that we highlighted 
and summarized above. Although it is indisputable that 
the articles we selected are important, they are not neces-
sarily the most important papers from this 2-year period. 
The adage that “beauty is in the eye of the beholder” holds 
true here, and in this instance, we (AAL and WAG) are 
the “beholders.” The selection of these particular notable 
papers arises from our own personal strategies for sur-
veillance of the literature, which are based on the prin-
ciples we have outlined here. High-quality health care 
implies practice that is consistent with best evidence, and 
all providers should develop their own strategies for in-
corporating evidence into practice.
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